TY  - JOUR
AU  - Bochtler, Tilmann
AU  - Hegenbart, Ute
AU  - Kunz, Christina
AU  - Benner, Axel
AU  - Kimmich, Christoph
AU  - Seckinger, Anja
AU  - Hose, Dirk
AU  - Goldschmidt, Hartmut
AU  - Granzow, Martin
AU  - Dreger, Peter
AU  - Ho, Anthony D
AU  - Jauch, Anna
AU  - Schönland, Stefan O
TI  - Prognostic impact of cytogenetic aberrations in AL amyloidosis patients after high-dose melphalan: a long-term follow-up study.
JO  - Blood
VL  - 128
IS  - 4
SN  - 1528-0020
CY  - Stanford, Calif.
PB  - HighWire Press
M1  - DKFZ-2017-01651
SP  - 594 - 602
PY  - 2016
AB  - Cytogenetic aberrations detected by interphase fluorescence in situ hybridization (iFISH) of plasma cells are routinely evaluated as prognostic markers in multiple myeloma. This long-term follow-up study aimed to assess the prognosis of systemic light chain amyloidosis (AL) patients treated with high-dose melphalan (HDM) chemotherapy and autologous stem cell transplantation, depending on iFISH results. Therefore, we analyzed a consecutive cohort of 123 AL patients recruited from 2003 to 2014. HDM was safe, with only 1 of 123 patients dying as a result of treatment-related mortality, and effective, with a complete remission (CR) rate of 34
KW  - Immunoglobulin Light Chains (NLM Chemicals)
KW  - Melphalan (NLM Chemicals)
LB  - PUB:(DE-HGF)16
C6  - pmid:27257181
DO  - DOI:10.1182/blood-2015-10-676361
UR  - https://inrepo02.dkfz.de/record/125525
ER  -